Interestingly, subcutaneous administration of antagomir-22 (APT-110) at a dose of 15 mg/kg on days 0, 2, 4 of week 1 of treatment and then once a week for a total of 8 or 12 weeks in mice with diet-induced obesity provides a sustained increase in energy expenditure, reduction in body mass of 30% and liver steatosis, decreases blood glucose, insulin, cholesterol, leptin levels, and alleviates insulin resistance [310,311]. This evidence concerns the gene INS and Insulin resistance.